Torrent Sees Decline In US Sales After Dropping Sartan Portfolio

As Company Continues To Grow Domestically

Torrent Pharma has reported a double-digit drop in its US revenues after discontinuing its sartan portfolio, due to the presence of trace amounts of N-nitrosodimethylamine. The company saw its domestic market grow aided by market share gains in high potential new launches.

Drop in revenues
Torrent reports a 30% drop in US revenues • Source: Alamy

Torrent Pharmaceuticals Ltd. has reported a 30% drop in its US revenues to INR2.69bn ($36.7m) in its financial fourth quarter ended 31 March 2021, and a 17% drop to INR12.61bn for the full financial year as “sales were impacted by price erosion on base business and base impact of sartan portfolio discontinuation.”

Due to the discovery of trace amounts of nitrosamines in sartans, including valsartan and losartan, several lots were recalled last...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business